On October 22, Argenx SE fell 3.11% in Regular Trading, trading at $885.885, with turnover of $111 million.
The clearest catalyst was the company’s latest quarterly earnings release: third-quarter EPS was $7.80, slightly below the $7.83 consensus estimate, while sales reached $1.751 billion, above the $1.664 billion expectation.
The move appears tied to investors focusing on the small profit miss after results were released. Recent trading had already been highly sensitive to pipeline updates, including positive phase 3 myositis data for Vyvgart Hytrulo, the discontinuation of a late-stage Sjogren’s disease trial, and progress in celiac disease, leaving expectations elevated around earnings quality and commercialization momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments